About
Therapix is building a specialty pharmaceutical company focused on significantly enhancing FDA-approved dronabinol for the treatment of Tourette Syndrome and Mild Cognitive Impairment.
Dr. Ascher Shmulewitz, MD, PhD
Interim Chief Executive Officer
Chairman of Therapix’s Board of Directors since January 2014, Dr. Shmulewitz has also served as a Board member since February 2013. With doctorate degrees in medicine and engineering, Dr. Shmulewitz spent much of his career as a successful inventor, investor and serial entrepreneur in the biomedical technologies field, facilitating a wide range of corporate collaborations. He founded and invested in over twenty-four life science companies – many of which enjoyed successful exits via merger & acquisition transactions with large medical device companies – including Arteria Corp., Circulation Inc., Labcoat Medical Ltd., NeoVision Corp, and X-Cardia Inc. In 1995, Dr. Shmulewitz co-founded San Francisco Science and the Incumed Group which both provide seed funding to promising companies. He also founded the private Israeli investment firm and incubator Medgenesis Partners Ltd. which has invested in over a dozen ventures. Between 1988 and 1992, Dr. Shmulewitz held senior executive positions at Advanced Technology Laboratories Inc.. He received his M.D. from The Technion Medical School, and a Ph.D. in Engineering from Tel Aviv University, Israel.
DR. ADI ZULOFF-SHANI, PhD
Chief Technology Officer
Dr. Adi Zuloff-Shani has served as Chief Technologies Officer at Therapix since February 2016, bringing with her more than 15 years of experience as an R&D executive. From 2012 until 2016, Dr. Zuloff–Shani served as a Vice President of Development at Macrocure Ltd. (NASDAQ: “MCUR”) where, aside from leading all research and development activities, she interacted, and was involved, with the activities of all departments including clinical, operations, quality assurance, quality control, finance, and regulatory affairs. Prior to that, Dr. Zuloff-Shani spent eight years as the Senior Scientist in the Research & Development Unit of Magen David Adom’s National Blood Services. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University, Israel.
DORON BEN AMI
Chief Strategy Officer
Mr. Doron Ben Ami has been Therapix’s Chief Strategy Officer since December 2015. A seasoned executive with more than 20 years of management experience, he has held various leadership roles in the multinational pharmaceutical industry. Mr. Ben Ami previously held a range of executive positions including Associate Vice President for the Eastern European and Israel region at Merck (from 2010 to 2015), Managing Director of the Merck subsidiary in Israel (from 2008 to 2010), and General Manager of Lundbeck Israel (from 2002 to 2008). Since 2015, Mr. Ben Ami has served as a Senior Consultant at The Harel Group Inc., a U.S. based business development advisory firm that connects innovative pharmaceutical companies with strategic partners. Mr. Ben Ami holds a Master of Health Systems Administration degree (M.H.A.) from Tel Aviv University, Israel.
